ArticleEuropean heart journal. Case reports2025
Drug challenge test for early symptom control in patients with coronary artery spasm: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Calcium channel blockers are the first-line treatment option, followed by long-acting nitrates or nicorandil as second-line medications for patient with coronary artery spasm (CAS). However, there are cases where symptoms cannot be controlled by a combination of these drugs. The drug choice after first- and second-line treatment options is varied and challenging. Case summary: A 70-year-old woman presented to our hospital with complaints of angina at rest. The patient was diagnosed with CAS based on a positive acetylcholine provocation test result. Nitrates were intolerable due to headaches. The combination of calcium channel blocker and nicorandil was not effective in mitigating her symptoms. Four potential symptom relief drugs-trimetazidine, shigyakusan, keishibukuryogan, and denopamine-were prescribed. Each drug was administered for one week, and symptom improvement was assessed one month later. Two drugs (shigyakusan and keishibukuryogan) were effective in relieving her symptoms, but neither was satisfactory on its own. Therefore, these two drugs were combined and added on top of the calcium channel blocker and nicorandil. Her symptoms were well controlled thereafter. Discussion: The drug challenge test, which involves prescribing various types of drugs for short durations to evaluate their effects, may be an effective option for quickly controlling symptoms in patients with refractory CAS who exhibit frequent symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.